Xueyan Wang

SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.

T. Annie T. Fong, Laura K. Shawver, Li Sun et al. · PubMed · 1999 · 1K citations

Medicine, Oncology, Pharmacology +16

Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19

Mei Zhou, Xueyan Wang, Darrin A. Lindhout et al. · Cancer Research · 2014 · 178 citations

Medicine, Cancer Biology, Oncology +16

MBX-8025, A Novel Peroxisome Proliferator Receptor-δ Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin

Harold Bays, Sherwyn Schwartz, Thomas Littlejohn et al. · The Journal of Clinical Endocrinology & Metabolism · 2011 · 148 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Extracellular Signal–Regulated Kinase 1/2 Mitogen-Activated Protein Kinase Pathway Is Involved in Myostatin-Regulated Differentiation Repression

Wei Yang, Yan Chen, Yong Zhang et al. · Cancer Research · 2006 · 139 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17

SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity

Shem Patyna, Alexander Laird, Dirk B. Mendel et al. · Molecular Cancer Therapeutics · 2006 · 103 citations

Medicine, Oncology, Pharmacology +17